For more information, referring candidate patients or any other questions please contact:

Rachel Wilschke, BA, COT

Clinical Research Trials Coordinator.
T 312-527-1880
F 312-527-2747
rachelwilschke@chicagolandretinal.com 


​1) SEQUOIA Study


​“SEQUOIA Study: The Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration.” A phase-3 double-masked study sponsored by Allergan, this study will determine change in baseline in BCVA in the study eye, change in baseline in central retinal thickness in the study eye, the percent of patients who gain >15 letters via ETDRS visual acuity testing, and change from baseline regarding patient responses on National Eye Institute Visual Functioning Questionnaire-25. Sites will randomize two different dosages of abicipar pegol and one dosage of ranibizumab as control, and the treatment will be administered in different intervals for a total of 96 weeks. The study began in June 2015, and will conclude in August 2018. Now enrolling at the following location: Chicagoland Retinal Consultants, 5215 N California Ave Suite F801, Chicago, IL 60625.

2) PALADIN Study


“ILUVIEN Study: A Phase 4 Safety Study of IOP Signals in Patients Treated with ILUVIEN (Fluocinolone Acetonide Intravitreal Implant) 0.19mg.”- Patients who are eligible to be part of the PALADIN study are those who are eligible for treatment with Iluvien based on Prescribing Information for Iluvien: it is indicated for the treatment of Diabetic Macular Edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (Iluvien Package Insert, December 2014). Excluded patients are those who are unable to understand and sign the Informed Consent Form.  Now enrolling in the following locations: Chicagoland Retinal Consultants, LLC, 5215 N. California Ave. Suite F801, Chicago, IL 60625; 6801 W. Stanley Ave. Suite B, Berwyn, IL 60402; and DEC LLC dba Hauser-Ross Eye Institute, 1630 Gateway Drive, Sycamore, IL 60178.

3) Dry Eye Cortisol Study


​“A Phase 2, Vehicle-controlled, Randomized, Dose-ranging Study of the Safety, Efficacy, Tolerability, and Systemic Pharmacokinetics of Ophthalmic Suspension in Patients with Dry Eye Disease.” Sponsored by Allergan. The study was closed at our Sycamore location on February 23, 2016.

4) ORBIT Study


“ORBIT- Ocriplasmin Research to Better Inform Treatment (TG-MV-018)” sponsored by Thrombogenics. Studying outcomes and safety in patients receiving the FDA-approved drug Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). Enrollment ended May 31, 2015. 

5) The MAKO Study

“A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.” Sponsored by Ohr Pharmaceutical. This two-year study will evaluate patients in two arms: In first year, (1) those receiving monthly ranibizumab and twice daily Squalamine lactate ophthalmic solution, 0.2%, and (2) those receiving monthly ranibizumab and twice daily placebo ophthalmic solution; in second year, subjects will continue with randomized study medication, and ranibizumab will be administered on a PRN basis- the need for subsequent injections of ranibizumab will be evaluated every 4 weeks (28 ± 7 days) based on OCT-guided retreatment criteria. Subjects who meet inclusion/exclusion criteria at Screening/Baseline and following confirmation of eligibility from the Central Reading Center will receive an injection of ranibizumab in the eligible study eye. At the Day-0 visit, after the initial ranibizumab injection, subjects will be randomly assigned to either the Squalamine or Placebo arm. Clinic visits for this protocol will occur approximately every 4 weeks, corresponding with the injections, and Primary efficacy assessment will be Week 36. Currently enrolling in the 5215 N. California office location- soon to be enrolling in the Berwyn and Hauser-Ross locations. 

Please contact the Study Coordinator for additional information: Rachel Wilschke 708-484-8500 ext. 427.